Research programme: T lymphocyte immunotherapies - Juno Therapeutics

Drug Profile

Research programme: T lymphocyte immunotherapies - Juno Therapeutics

Alternative Names: CAR T cell products - Juno Therapeutics; CARTs - Juno Therapeutics; Chimeric antigen receptor T lymphocytes - Juno Therapeutics; High-affinity TCR T cells; TCR T cell products - Juno Therapeutics

Latest Information Update: 22 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Juno Therapeutics
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics; Memorial Sloan-Kettering Cancer Center; Seattle Childrens Research Institute
  • Class CAR-T cell therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 16 Nov 2016 Juno Therapeutics plans a phase I trial for Solid tumours in Australia (ACTRN12616001580460)
  • 11 Apr 2016 T lymphocyte immunotherapies licensed to Celgene worldwide except North America and China
  • 04 Dec 2013 Preclinical trials in Haematological malignancies in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top